Learn more about HaemaLogix’s ground-breaking KappaMab technology Posted on February 16th, 2022 . Updated on March 25th, 2022 by Paul LangleyKappaMab is a monoclonal antibody developed by HaemaLogiX to treat blood cancers, with an initial focus on multiple myeloma.